13F Holdings
中文EN

YDES YD Bio Ltd Annual reports only

Services-Medical Laboratories · Nasdaq · SEC CIK 2011674 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY16.9%
TTM net income YoY-488.8%
TTM EPS YoY-500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin28.1%
Operating margin-883.3%
Net margin-1,392.6%
FCF margin-1,346.6%
EBITDA margin-880.6%

Returns

ROE-445.1%
ROA-80.5%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets120.7%
Debt / equity—
Current ratio5.88x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue241.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$596,817$510,360$350,131
Cost of revenue$429,407$355,004$196,686
Gross profit$167,410$155,356$153,445
R&D expense$1.60M$491,353—
SG&A expense$3.66M$1.12M$153,069
Operating income-$5.27M-$1.46M-$9,847
Interest expense—$772$2,144
Pretax income-$8.31M-$1.39M$17,650
Income tax-$1,531$25,080$4,090
Net income-$8.31M-$1.41M$13,560
EBITDA-$5.26M-$1.45M-$7,395
EPS (basic)-0.12-0.020.00
EPS (diluted)-0.12-0.020.00
Weighted avg. shares (diluted)66.72M64.73M64.73M
Balance sheet
Cash & equivalents$6.01M$3.13M$87,098
Receivables$167,477$86,582—
Inventory$1.88M$37,335—
Current assets$9.67M$3.47M—
PP&E, net$59,340$64,379—
Intangibles$2.61M$2.68M—
Total assets$13.78M$6.86M—
Current liabilities$1.64M$263,060—
Long-term debt$6,764——
Total debt$6,764——
Total liabilities$16.64M$273,980—
Shareholders' equity-$2.86M$6.59M$22,994
Net debt-$6.00M——
Shares outstanding70.79M64.73M—
Cash flow statement
Operating cash flow-$6.60M-$1.22M-$55,657
Capital expenditure$1.44M$74,914$290
Free cash flow-$8.04M-$1.30M-$55,947
Investing cash flow-$1.44M-$2.90M-$290
Financing cash flow$10.87M$7.11M$113,887
Depreciation & amortization$16,246$10,199$2,452

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.